Compare Sanofi SA (SNY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wix.Com Ltd — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Wix.Com Ltd trades at $53.52 (market cap $2.23B). The key difference: Sanofi SA is far larger — about 47× Wix.Com Ltd's market cap, and Sanofi SA pays a 5.5% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| SNY | WIX | |
|---|---|---|
Market Cap | $104.83B | $2.23B |
Sector | Health | Technology |
52-Week High | $52.34 | $184.24 |
52-Week Low | $41.33 | $40.43 |
Enterprise Value | $121.32B | $1.80B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Wix.com trades at $51.12, down 0.64% on the day, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. Revenue growth remains strong, reaching $1.99B in 2025, though net income margin turned negative at -1.97%. Recent news includes product launches like Wix Headless AI integration and multiple law firm investigations into potential securities fraud following a 56% stock decline in H1 2026.
The stock presents a high-risk, high-reward profile with a consensus price target of $77.50 implying 52% upside, but faces headwinds from earnings volatility, negative equity, and legal scrutiny. Long-term growth drivers in AI and small business tools are countered by near-term execution risks and competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
